This milestone validates the facility’s quality systems and manufacturing controls following a $38 million expansion finalized in 2023. The site now hosts advanced analytical laboratories and chemical development suites, specifically optimized to handle lower-volume production runs. With reactor capacities reaching 2,000 liters, the facility is positioned to support orphan drugs, precision medicines, and other highly specialized therapies designed for smaller patient populations.

Chief Executive Officer Thomas Loewald noted that the site’s design addresses a growing industry demand for flexible, small-scale commercial manufacturing. By integrating these capabilities, Cambrex now offers a streamlined pipeline that carries customer programs from initial development through long-term market supply. This expansion strengthens the company's North American footprint, providing a bridge between early-stage innovation and final product delivery for clients worldwide.